Janet Hopkins
Chief Tech/Sci/R&D Officer at AURA BIOSCIENCES, INC.
Net worth: 1 M $ as of 2024-03-30
Profile
Janet Jill Hopkins is currently the Director at Gyroscope Therapeutics Holdings Plc and the Chief Medical Officer at Aura Biosciences, Inc. She previously served as the Chief Executive Officer at Gyroscope Therapeutics Ltd.
and the SVP & Global Head-Ophthalmology at Novartis AG.
Hopkins holds a doctorate degree from McMaster University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
AURA BIOSCIENCES INC
0.33% | 2024-01-31 | 163,515 ( 0.33% ) | 1 M $ | 2024-03-30 |
Janet Hopkins active positions
| Companies | Position | Start |
|---|---|---|
| GYROSCOPE THERAPEUTICS HOLDINGS PLC | Director/Board Member | 2022-02-16 |
| AURA BIOSCIENCES, INC. | Chief Tech/Sci/R&D Officer | 2023-10-15 |
Former positions of Janet Hopkins
| Companies | Position | End |
|---|---|---|
| NOVARTIS AG | Corporate Officer/Principal | 2023-09-30 |
Gyroscope Therapeutics Ltd.
 Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Gyroscope Therapeutics Ltd. operates as an ophthalmology firm. It develops a cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system. The company was founded on April 18, 2016 and is headquartered in Stevenage, the United Kingdom. | Chief Executive Officer | 2023-09-30 |
Training of Janet Hopkins
| McMaster University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| AURA BIOSCIENCES, INC. | Health Technology |
| NOVARTIS AG | Health Technology |
| Private companies | 2 |
|---|---|
Gyroscope Therapeutics Ltd.
Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Gyroscope Therapeutics Ltd. operates as an ophthalmology firm. It develops a cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system. The company was founded on April 18, 2016 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
Gyroscope Therapeutics Holdings Plc
 Gyroscope Therapeutics Holdings Plc BiotechnologyHealth Technology Gyroscope Therapeutics Holdings Plc engages in the development of gene therapy beyond rare diseases. It focuses on age-related macular degeneration. The company was founded in 2016 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
- Stock Market
- Insiders
- Janet Hopkins
